California’s Attorney General recently appealed to the Ninth Circuit Court to reverse a decision by a district court concerning the state’s legislation on “reverse payment” settlements. These settlements, often involving brand-name and generic-drug manufacturers, have been a subject of legal and regulatory scrutiny. The core of the appeal challenges the limitation imposed by the court that restricts application of these laws to deals made solely within California. The Attorney General’s argument suggests that such limitations undermine the law’s intent to prevent anti-competitive agreements that could affect drug prices and market fairness.
For further details on this legal development, read more on Law360.